ERBB2 and cancer: To examine the HER2-specific cytotoxicity contributed by ACC technology and ADCC, the cytotoxicity of ACE-oNK-HER2 or Ctrl-oNK were incubated with HER2+ cancer cells in the presence of various concentrations of trastuzumab.